News

AN2728 is a boron-based small-molecule compound which inhibits the activity of phosphodiesterase-4 (PDE4), thereby reducing the generation of pro-inflammatory cytokines that are the precursors of the inflammation associated

Makena, sponsored by US-based Hologic, is indicated for pregnant women with a history of at least one spontaneous preterm birth. The drug is not intended for women with

Synexus announced its plans to be involved in ophthalmology trials last October after discussions with leading sponsors. The trial will be conducted on behalf of a pharmaceutical company

INT0022 has been developed using IntelGenx’ proprietary immediate release ‘VersaFilm’ drug delivery technology The randomised, two-period, two-way crossover study in healthy male subjects was designed to evaluate whether

In the study, Inovio researchers investigated whether the electrical field strength generated by piezoelectricity alone could elicit gene transfer in the skin of an animal. Researchers injected a

The Wiley Protocol, the brainchild of Wiley, is a trademarked, patent-protected, bio-identical hormone replacement therapy (HRT) delivery system consisting of biomimetic estradiol and progesterone in a topical cream

The Zolpimist Oral Spray unit contains 60 metered sprays and provides the flexibility of administering either a 5 or 10 mg dose of the zolpidem active ingredient, ECR

17P will now be marketed under the brand name Makena and given in weekly injections to pregnant women between 16 and 20 weeks gestation, continuing until 37 weeks

Palatin has been granted an extension until 26 May 2011 to regain compliance with stockholders’ equity requirements under Section 1003(a)(iii) of the NYSE Amex Company Guide, and until